Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11630MR)

This product GTTS-WQ11630MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11630MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ81MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ4642MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ11880MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ3017MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ2755MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ7195MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ6061MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ9158MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW